• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

Another bad launch of Viekira from Abbott/Abbvie

Quote

Anonymous

Guest
Almost a month in....Not enough materials sent to the reps to even have enough to distribute to all their customers, no PROCEED materials, and best of all...NO reprints to hand out. Thanks, Abbvie for sending the sales force out there to a major battle with hardly any armor! That National sales meeting was such a FARCE! Home office People walking around arrogant and acting like they are ready to go and in top of everything....what the hell have you guys been doing all year?????? Sales force should have had all the necessary materials on day one and....love the fact that there has been hardly any communication from home office ...just the sales force themselves having to make phone calls to get adequate answers.

Definition of insanity, Abbvie, doing the same things and expecting a different result...so with that you can take your 51% and shove it up your ass!
 








Anonymous said:
I agree on the awful start and makes us look very bad in the field. When you try to sell your drug on cost and contracts you are in a lot of trouble!
Click to expand...

It's been an embarrassment! Selling from the PI and not having any reprints to hand out..."but hey doc..you can go to the New England Journal of a medicine and find our studies there" what crap! Providers do not want to have to look anything up...they just want the necessary materials from sales in their hands...printed...so they can view it easily.

Abbvie wants to play with the big boys....I was hoping for a launch to finally go right at this company...but NO...same shitty launch as they always do with every drug that has ever launched at this company. It's mind boggling how tacky and ridiculous this launch has gone thus far. Screw anymore conference calls with Acuff..what does that matter? web ex radio broadcasts...scripted and strange...ughhhhhh. We're in trouble!
 




I have your package insert. All 51 pages. I also have the Ritonovir PI and the Riboviron PI. Why do you say you have an HIV indication? Sec 1.1 say HVC genotype 1 with or without cirrhosis! No indication for HIV only database.
 




Anonymous said:
I have your package insert. All 51 pages. I also have the Ritonovir PI and the Riboviron PI. Why do you say you have an HIV indication? Sec 1.1 say HVC genotype 1 with or without cirrhosis! No indication for HIV only database.
Click to expand...

You're an idiot troll! You do not need a PI for ritonavir dumbass because it is at a baby dose of 100mg...only as a PK booster. If you knew most HIV patients would take 600mg BID...so at 100mg it is very small. Also, idiot....Viekira has an HCV/HIV con-infected indication (as in a patient has BOTH HIV and HCV)moron not for HIV alone. Ribavirirn PI providers are very familiar with...so...that's not an issue. If you're a Gilead troll...which I suspect you are....I would highly suggest you read the PI thoroughly and all of our phase III clinical trials with over 2300 patients and know your stuff before you spew mis information. Harvoni's clinical trials do not touch Viekiras clinical trials with a 10 ft pole...our studies are robust and easily segmented unlike Harvomi which is pooled, extrapolated, no division on what Treatmemt Experienced actually means unlike our data of an experienced patient it is clearly defines as to which patients those actually are (null responders, prior relapsers etc.) There is a dedicated not pooled analysis of viekira paks HCV with cirrhosis of 380 patients compared to Harvoni...what is it like 30+ cirrhotics...oh and if you want 12 weeks of Harvoni instead of 24 in the cirrhotic patient ribavirin was recommended as an add on to Harvoni by AASLD so..yeah...

Viekira Pak is a great drug with excellent clinical backing behind it....the DDI's ALL can be substituted for something else, dose modified, or no dose adjustment. There is also no adjustment needed for mild, moderate, or severe renal impairment unlike Harvoni which didn't study crap and has "NOT RECOMMENDED" listed throughout their PI which if I was a provider wouldn't make me too comfortable. Viekira Pak PI is honest and straightforward so patients can get the Highest cure rate and safety. Harvoni PI is vague in several sections.

Abbvie just needs to support their sales teams better by giving them the materials they need to do their job most effectively.
 




Anonymous said:
You're an idiot troll! You do not need a PI for ritonavir dumbass because it is at a baby dose of 100mg...only as a PK booster. If you knew most HIV patients would take 600mg BID...so at 100mg it is very small. Also, idiot....Viekira has an HCV/HIV con-infected indication (as in a patient has BOTH HIV and HCV)moron not for HIV alone. Ribavirirn PI providers are very familiar with...so...that's not an issue. If you're a Gilead troll...which I suspect you are....I would highly suggest you read the PI thoroughly and all of our phase III clinical trials with over 2300 patients and know your stuff before you spew mis information. Harvoni's clinical trials do not touch Viekiras clinical trials with a 10 ft pole...our studies are robust and easily segmented unlike Harvomi which is pooled, extrapolated, no division on what Treatmemt Experienced actually means unlike our data of an experienced patient it is clearly defines as to which patients those actually are (null responders, prior relapsers etc.) There is a dedicated not pooled analysis of viekira paks HCV with cirrhosis of 380 patients compared to Harvoni...what is it like 30+ cirrhotics...oh and if you want 12 weeks of Harvoni instead of 24 in the cirrhotic patient ribavirin was recommended as an add on to Harvoni by AASLD so..yeah...

Viekira Pak is a great drug with excellent clinical backing behind it....the DDI's ALL can be substituted for something else, dose modified, or no dose adjustment. There is also no adjustment needed for mild, moderate, or severe renal impairment unlike Harvoni which didn't study crap and has "NOT RECOMMENDED" listed throughout their PI which if I was a provider wouldn't make me too comfortable. Viekira Pak PI is honest and straightforward so patients can get the Highest cure rate and safety. Harvoni PI is vague in several sections.

Abbvie just needs to support their sales teams better by giving them the materials they need to do their job most effectively.
Click to expand...

Thanks. Are you the MSL that made an arse of yourself at the Liver Meeting? Party On!
 








You clearly have not read our PI. Ours is very simple and clear. And we can be used in mild to moderate renal impairment. Harvoni not studied in severe renal. VPK was not studied in severe either. Your interpretation is only theoretical. We did include F3 in our cirrhotic trials. You cherry picked patients. Your studies were also 90% whites. Nice real world interpritation. Our drug interactions are very few. i appreciate the passion but clearly there is one winner from treaters perspective and a patient perspective and that's what matters. The Insurance thing will be mute point in 3 months.
 












Anonymous said:
We did not include f3 scores in our cirrhotics.....sorry fast typing.
Click to expand...

Oh...to the contrary....with Viekira Pak there is NO dose adjustment needed for mild, moderate, OR...SEVERE renal impairment...not studied in patients on dialysis ...but definitely studied in severe renal impairment HCV patients. You keep saying section 1.1...it's just 1 and I see it doesn't say HIV/HCV con infection or Post liver transplant indication...but it clearly has dosage and administration recommendations listed on page 1 for both HIV/HCV con-infected and post transplant with accompanying studies outlined in section 14.5 and 14.6 small, but statistically significant studies! Okay...so we have more whites in the st..so what? harvoni has small numbers in their studies...ion 1 865 patents , 85% white, ion2 440 patients, 81% white, ion3 647 patients, 78% white....1952 ....approx 56 TOTAL cirrhotic patients compared to our 380...and you do not have clear distinction on what "treatment experienced means" like we a viekira does...Harvoni does NOT have a dedicated trial of just cirrhotic patients. You need to extrapolate all harvonis out and alright...I'll give you your studied in "child Puh B and C" versus ours of just A, but viekira has phase III going for B.

Look....both are great medications...the only patients I'm asking for is the 1B non-cirrhotic which hands down beats Harvoni...and it doesn't need ribavirin. And I'll take all of the 1a and 1b child Puh A cirrhotics...because our clinical trial on those patients is really better than Harvoni especially when you look at the relapse rate of Harvoni in these patients.

Tit for tat really...there's enough business for everyone...and yes..you'll probably trump us in the managed care department because we have morons at headquarters...but it's not the reps fault. We've been given dull putty knives to bring to a gun fight.
 




Anonymous said:
You're an idiot troll! You do not need a PI for ritonavir dumbass because it is at a baby dose of 100mg...only as a PK booster. If you knew most HIV patients would take 600mg BID...so at 100mg it is very small. Also, idiot....Viekira has an HCV/HIV con-infected indication (as in a patient has BOTH HIV and HCV)moron not for HIV alone. Ribavirirn PI providers are very familiar with...so...that's not an issue. If you're a Gilead troll...which I suspect you are....I would highly suggest you read the PI thoroughly and all of our phase III clinical trials with over 2300 patients and know your stuff before you spew mis information. Harvoni's clinical trials do not touch Viekiras clinical trials with a 10 ft pole...our studies are robust and easily segmented unlike Harvomi which is pooled, extrapolated, no division on what Treatmemt Experienced actually means unlike our data of an experienced patient it is clearly defines as to which patients those actually are (null responders, prior relapsers etc.) There is a dedicated not pooled analysis of viekira paks HCV with cirrhosis of 380 patients compared to Harvoni...what is it like 30+ cirrhotics...oh and if you want 12 weeks of Harvoni instead of 24 in the cirrhotic patient ribavirin was recommended as an add on to Harvoni by AASLD so..yeah...

Viekira Pak is a great drug with excellent clinical backing behind it....the DDI's ALL can be substituted for something else, dose modified, or no dose adjustment. There is also no adjustment needed for mild, moderate, or severe renal impairment unlike Harvoni which didn't study crap and has "NOT RECOMMENDED" listed throughout their PI which if I was a provider wouldn't make me too comfortable. Viekira Pak PI is honest and straightforward so patients can get the Highest cure rate and safety. Harvoni PI is vague in several sections.

Abbvie just needs to support their sales teams better by giving them the materials they need to do their job most effectively.
Click to expand...

Nice try Abbvie homer! Harvoni works in cirrhotics and non-cirrhotics. You can't compare trials but since you are going there, take a look at how severe your patients were in your trials vs. harvoni's. Harvoni's efficacy is there without the need for riba, or Ritonavir all in one pill. Oh by the way, don't forget to mention the huge list of drugs that interact because of the P450 issue. Oh also, since Sovaldi is part of Harvoni, don't forget the year plus experience of patients achieving SVR and how that resonates with your providers. good night now!
 








no BMI over 30, f3 included in cirrhotic data, and one of my favorite lines in the VKP PI, Tqse II 95% white, 3% Black / African American and 12 % Latino for a nice 110%. What....
 




Anonymous said:
no BMI over 30, f3 included in cirrhotic data, and one of my favorite lines in the VKP PI, Tqse II 95% white, 3% Black / African American and 12 % Latino for a nice 110%. What....
Click to expand...

Our R&D is pitiful!! They can't count to 100 and they develop a BID 600 tablets (including the holy pill, ritonavir) regimen for 2015!!!! OMG get me out of this sh*Thole!
 




Watching this from outside (not Gilead either), so glad that I didn't bite on the hard sell mgmt made to get me on board. Sorry to hear and see that it isn't what everyone was hoping. You live or die by how you launch, rarely if ever can you re-launch a few months out as perceptions have become reality.
 








Anonymous said:
Just go to Staples and make copies of the studies for your customers. I also made copies of key web pages. You have to be creative to sell!!
Click to expand...

That is sooooo non compliant, however....at this point...it could very well be a necessity if they (HQ) cannot get their crap together. Let's hope the newest box we got on Saturday has some useful things in it?
 












Top Bottom
Back
Quote